Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical ...

Mantle cell lymphoma (MCL) is often an aggressive form of cancer traditionally treated with chemotherapy, immunotherapy, and stem cell transplants when appropriate. Emerging therapies may offer more ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and aggressive ...

Patients with high-risk treatment-refractory mantle cell lymphoma (MCL) show significant survival benefits with treatment with mosunetuzumab combined with polatuzumab vedotin (mosun-pola), new ...

Please provide your email address to receive an email when new articles are posted on . HSCT did not benefit patients with mantle cell lymphoma in complete remission with undetectable minimal residual ...

A phase 1/2 trial of BeOne Medicines’ sonrotoclax has hit its primary endpoint, furthering the biotech’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma (MCL). The single-arm ...

The FDA has assigned a PDUFA date of May 23, 2024 for the relapsed/refractory FL indication and May 31, 2024 for the relapsed/refractory MCL indication. The Food and Drug Administration (FDA) has ...

Determining the presence of mantle cell lymphoma involves a physical examination, microscopic analysis, genetic screening, and specialized antigen tests. Your body’s lymphatic system is made up of ...